Emergent BioSolutions Secures $52.7M Smallpox Vaccine Contract Modification

Key Facts

1Emergent BioSolutions announced a $52.7M contract modification from the U.S. HHS to supply ACAM2000 smallpox vaccine.

Amid continued focus on bolstering biosecurity stockpiles, Emergent BioSolutions announced a $52.7 million contract modification from the U.S. Department of Health and Human Services (HHS) to supply the ACAM2000 smallpox vaccine, according to a company statement via GlobeNewswire. The modification supports smallpox preparedness and response needs for the Administration for Strategic Preparedness and Response (ASPR).

The contract underscores ongoing government reliance on the ACAM2000 vaccine within the national stockpile. Per market data, EBS stock closed at $8.53 on June 26, 2026, trading between $7.95 and $8.53 during the session. Government contracts like this provide revenue visibility for the company amid steady demand for biodefense vaccination solutions.

From a technical perspective, EBS shares remain range-bound, with a break above $8.53 (session high) or below $7.95 (session low) potentially signaling the next trend. Fundamentally, additional government awards or the company's upcoming earnings results could serve as key catalysts for investors in the biodefense sector.